Adagene Reports Promising ADG126 Study Results at ASCO

Adagene ( (ADAG) ) has provided an update.

Adagene Inc. announced updated data from its Phase 1b/2 study of ADG126 in combination with KEYTRUDA for treating advanced microsatellite stable colorectal cancer. The study showed promising results with a 29% overall response rate in the 20 mg/kg cohort, demonstrating reduced treatment-related toxicities and durable responses. These findings, presented at the ASCO Annual Meeting on May 22, 2025, highlight the potential of ADG126 to improve therapeutic outcomes for patients, supporting further clinical development discussions with regulatory bodies.

The most recent analyst rating on (ADAG) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Adagene stock, see the ADAG Stock Forecast page.

Spark’s Take on ADAG Stock

According to Spark, TipRanks’ AI Analyst, ADAG is a Neutral.

Adagene has a challenging financial outlook with substantial losses and declining revenues, leading to a low financial performance score. The technical indicators are mixed, showing weak bullish momentum. Valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors contribute to a cautious outlook on the stock.

To see Spark’s full report on ADAG stock, click here.

More about Adagene

Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies. The company utilizes computational biology and artificial intelligence to design antibodies that address unmet patient needs globally. Adagene’s proprietary technologies, including SAFEbody, aim to enhance the safety and efficacy of antibody therapeutics by using precision masking technology.

Average Trading Volume: 26,496

Technical Sentiment Signal: Sell

Current Market Cap: $73.49M

For an in-depth examination of ADAG stock, go to TipRanks’ Stock Analysis page.